Intuitive Surgical, Inc. $ISRG Shares Sold by Horizon Investments LLC

Key Points

• Horizon Investments LLC reduced its stake in Intuitive Surgical, Inc. by 6.9% in the first quarter, holding shares worth approximately $5.48 million at the end of the period.
• Analyst ratings for Intuitive Surgical vary, with a consensus rating of "Moderate Buy", and the average price target is around $595.95 following recent upgrades by several research firms.
• Intuitive Surgical reported a 21.4% year-over-year revenue increase with earnings of $2.19 per share, exceeding analysts' expectations of $1.93, during its most recent earnings report.

Horizon Investments LLC reduced its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 6.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,064 shares of the medical equipment provider's stock after selling 820 shares during the quarter. Horizon Investments LLC's holdings in Intuitive Surgical were worth $5,480,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Chilton Capital Management LLC grew its stake in Intuitive Surgical by 614.3% in the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 43 shares in the last quarter. Parvin Asset Management LLC bought a new position in Intuitive Surgical in the 4th quarter worth about $26,000. Global Financial Private Client LLC grew its stake in Intuitive Surgical by 253.3% in the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 38 shares in the last quarter. Elite Financial Inc. bought a new position in Intuitive Surgical in the 1st quarter worth about $26,000. Finally, LFA Lugano Financial Advisors SA bought a new position in Intuitive Surgical in the 1st quarter worth about $30,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Intuitive Surgical

In other news, insider Gary S. Guthart sold 2,800 shares of Intuitive Surgical stock in a transaction on Monday, July 28th. The shares were sold at an average price of $495.24, for a total transaction of $1,386,672.00. Following the completion of the sale, the insider directly owned 18,520 shares in the company, valued at approximately $9,171,844.80. The trade was a 13.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Mark Brosius sold 216 shares of Intuitive Surgical stock in a transaction on Friday, June 6th. The stock was sold at an average price of $563.11, for a total transaction of $121,631.76. Following the sale, the senior vice president owned 907 shares of the company's stock, valued at $510,740.77. The trade was a 19.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 15,839 shares of company stock worth $7,896,972. Company insiders own 0.70% of the company's stock.

Intuitive Surgical Stock Performance

ISRG traded up $3.18 during trading on Friday, hitting $480.26. The stock had a trading volume of 1,436,064 shares, compared to its average volume of 2,169,233. The company has a market capitalization of $172.16 billion, a PE ratio of 66.98, a PEG ratio of 5.03 and a beta of 1.59. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $616.00. The stock has a 50 day simple moving average of $508.75 and a two-hundred day simple moving average of $524.77.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, topping the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The business had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.35 billion. During the same period in the previous year, the firm posted $1.78 earnings per share. The business's revenue for the quarter was up 21.4% compared to the same quarter last year. On average, equities research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. UBS Group increased their price objective on shares of Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. Erste Group Bank reiterated a "hold" rating on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Citigroup reiterated a "buy" rating and set a $650.00 price objective (up from $590.00) on shares of Intuitive Surgical in a research note on Thursday, May 22nd. BTIG Research increased their price objective on shares of Intuitive Surgical from $566.00 to $571.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Intuitive Surgical from a "hold" rating to a "sell" rating and dropped their price objective for the company from $515.00 to $440.00 in a research note on Monday, June 9th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $595.95.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.